AI Article Synopsis
- - Low-grade serous ovarian carcinomas (LGSC) show poor chemotherapy response and are characterized by the activation of the RAS signaling pathway.
- - Researchers discovered recurring mutations in specific proteins using advanced genetic sequencing techniques; notably, mutations in the RAS pathway did not overlap with these other mutations.
- - The study found that mutant proteins worked together to enhance the growth and survival of LGSC cells, highlighting a novel mechanism of co-occurring mutations in ovarian cancer that promote tumor growth.
Article Abstract
Low-grade serous ovarian carcinomas (LGSC) are associated with a poor response to chemotherapy and are molecularly characterized by RAS pathway activation. Using exome and whole genome sequencing, we identified recurrent mutations in the protein translational regulator and in , and RAS pathway mutations were mutually exclusive; however, we found significant co-occurrence of mutations in and Missense mutations were clustered at the N-terminus of the protein in a region associated with its role in ensuring translational initiation fidelity. Coexpression of mutant and proteins promoted proliferation and clonogenic survival in LGSC cells, providing the first example of co-occurring, growth-promoting mutational events in ovarian cancer. .
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1158/0008-5472.CAN-16-2224 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!